Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

Status:	Archived
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	May 2003
End Date:	May 2018

Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors

Before the transplant, the patient will have a pre-transplant evaluation. This will help
find out whether there are health problems that will prevent the transplant. It also
provides "baseline" tests that will be used later to see whether or not organs have gotten
better or worse after the transplant. Prior to the stem cell collection, the patient will
get chemotherapy to help try to put him/her in remission and to push more stem cells into
the peripheral blood (mobilization). The study doctor will decide which chemotherapy will
be used for this part of the study. Once mobilization is completed, the peripheral blood
stem cell collection (apheresis) will be done in the clinic. The apheresis machine will draw
blood out of the central line. The blood then passes through the apheresis machine and the
stem cells are separated out. The remaining blood is sent back through the central line.
If the investigators are unable to collect enough peripheral blood stem cells, a bone marrow
harvest may be necessary to collect more stem cells.

The patient will then be admitted to the hospital for the first transplant. He/she will get
Thiotepa and Cyclophosphamide. Then the patient will be given back the cells that were
collected. The cells are given in the same manner as a blood transfusion. The patient will
be kept in the hospital until he/she is stable and blood counts are increasing.
Approximately 6 to 8 weeks after Day 0 of the 1st transplant, the patient will be admitted
for the second transplant. At this time, he/she will get Busulfan and Melphalan and then
the collected cells will be given back. The patient will be kept in the hospital until
he/she is stable and blood counts are increasing. Frequent clinic follow-up is required.

This study is open to patients who are less then 21 years of age with refractory or relapsed
high-risk, solid tumors, excluding neuroblastoma (there is a cooperative group trial for
these patients). Patients will be identified by the Transplant team and eligibility will be
verified by a member of the clinical research team. Patients will be cared for by members
of the Transplant team and various other subspecialty physicians.

The optimal treatment for refractory (disease won't go away with standard treatment) or
relapsed (disease comes back after going away) solid tumors is unknown. Recent studies have
shown some benefit to tandem peripheral blood stem cell transplantation (PBSCT). In a tandem
transplant, two transplants are done, one after the other. To do a PBSCT, stem cells
("mother cells" that can become any other type of cell) are first collected from the
patient's circulating blood. The patient then undergoes high-dose chemotherapy called the
preparative regimen. The preparative regimen destroys not only the tumor cells, but it also
destroys all of the normal blood making cells. The collected cells are then given back to
the patient to "rescue" the patient from the devastating effects of the preparative regimen.
By using a stem cell rescue will are able to give much higher doses of chemotherapy than we
would be able to give without the stem cell rescue. To make sure that all of the tumor
cells are destroyed, patients in this study will undergo two separate transplants using two
different preparative regimens. The preparative regimens will use the best agents that
have been found to work against recurrent and refractory solid tumors: Busulfan, Thiotepa,
Cyclophosphamide and Melphalan.

We found this trial at

sites

Emory University

201 Dowman Dr
Atlanta, Georgia 30303

(404) 727-6123